BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the first stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the first...
Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a definitive asset purchase, supply and support agreement with closely-held L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. of Italy, through which...
Vital Therapies’ (NASDAQ:VTL) VTL-308 Phase 3 trial to evaluate its cell-based therapy, ELAD, in subjects with severe alcoholic hepatitis has reached its enrollment target of 150 subjects. Subjects in VTL-308 were...
A Canadian Press piece appearing in several newspapers and broadcast news reports features closely-held Scientus Pharma and other companies as they look beyond legalization of recreational cannabis this summer to...
Ortho Regenerative Technologies (CSE:ORTH) has received a notice of allowance from the European Patent Office that when issued, will provide intellectual property protection for the composition of matter of its Ortho-R...
Profound Medical (TSXV:PRN) has entered into an agreement with a syndicate of underwriters, led by Canaccord Genuity, to sell on a bought deal basis a total of 30 million units at a price of $1 each for gross proceeds...
VolitionRx (NYSE American:VNRX) announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark, with...
Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study included 59 urine samples (28...
Closely-held RPS Diagnostics and Atomo Diagnostics of Australia have entered into a commercial and development partnership to create next generation FebriDx tests that are anticipated to transform the diagnosis of...
Closely-held Scientus Pharma has completed a private placement of common shares at a price of $4 each for gross proceeds of approximately $15.8-million. Net proceeds will be used for working capital and general...
Evotec AG (Frankfurt Stock Exchange:EVT) and MaRS Innovation announced the first project to be developed under their LAB150 partnership would target an unmet medical need in skin inflammatory conditions. The project...
DarioHealth (NASDAQ:DRIO) has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of the art...
DarioHealth (NASDAQ:DRIO) has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes that will use DarioHealth to run and track blood glucose...
Lipocine (NASDAQ:LPCN) announced receipt of $10-million in January by means of a loan and security agreement with Silicon Valley Bank. “This debt facility strengthens our balance sheet and provides increased...
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed patient enrollment in the TACT pivotal study designed to further evaluate safety and efficacy of its TULSA-PRO medical device to ablate prostate tissue in patients...
Ortho Regenerative Technologies (CSE:ORTH) announced that a peer-reviewed article detailing the tissue regeneration properties of its implants was published in the current issue of Journal of Tissue Engineering and...
Pixium Vision (FR0011950641-PIX) announced the first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss...
Titan Pharmaceuticals (NASDAQ:TTNP) is in discussions with Braeburn Pharmaceuticals about their partnership for the development and commercialization of Probuphine, the first six-month maintenance treatment of opioid...
NeutriSci International (OTCQB:NRXCF; TSX-V:NU; FRANKFURT:1N9) and Scientus Pharma have entered into a major R&D memorandum of understanding to share their technologies to develop, test, produce, and distribute a...
Profound Medical (OTCQX:PRFMF; TSXV:PRN) expects revenue of about $1.9-million for the fourth quarter of 2017, compared to nil in the year earlier quarter, and up about 30% sequentially from the third quarter of 2017...
Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54...
Ortho Regenerative Technologies (CSE:ORTH.CN) announced that a peer-reviewed article entitled, “Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine...